Boston Trust Walden Corp Lowers Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Boston Trust Walden Corp decreased its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 1.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 819,282 shares of the company's stock after selling 12,345 shares during the period. Boston Trust Walden Corp owned 1.65% of Prestige Consumer Healthcare worth $70,434,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its stake in shares of Prestige Consumer Healthcare by 5.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company's stock valued at $49,667,000 after buying an additional 33,844 shares during the period. Norges Bank acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $40,009,000. BNP Paribas Financial Markets increased its stake in shares of Prestige Consumer Healthcare by 1,073.3% in the fourth quarter. BNP Paribas Financial Markets now owns 203,903 shares of the company's stock valued at $15,923,000 after buying an additional 186,524 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in shares of Prestige Consumer Healthcare by 14.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,315 shares of the company's stock valued at $649,000 after buying an additional 1,030 shares during the period. Finally, Principal Financial Group Inc. boosted its position in shares of Prestige Consumer Healthcare by 3.2% during the 4th quarter. Principal Financial Group Inc. now owns 256,526 shares of the company's stock valued at $20,032,000 after purchasing an additional 7,890 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on PBH shares. Wall Street Zen upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, May 17th. Royal Bank Of Canada upgraded Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $93.33.

Prestige Consumer Healthcare Stock Down 0.3%

NYSE:PBH traded down $0.27 on Friday, hitting $83.37. The stock had a trading volume of 362,361 shares, compared to its average volume of 298,971. The business's fifty day moving average is $83.93 and its 200 day moving average is $82.51. The company has a market cap of $4.12 billion, a PE ratio of 19.43, a P/E/G ratio of 2.50 and a beta of 0.45. The company has a quick ratio of 2.82, a current ratio of 4.20 and a debt-to-equity ratio of 0.55. Prestige Consumer Healthcare Inc. has a 52 week low of $64.94 and a 52 week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.02. The business had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The company's quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.02 earnings per share. On average, equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.